IngredientsCapsiate is a naturally occurring phenolic ester and the principal member of a structural class of compounds known as capsinoids. By formal chemical definition (ChEBI), capsiate is a carboxylic ester obtained by formal condensation of the carboxy group of (6E)-8-methylnon-6-enoic acid with the benzylic hydroxy group of vanillyl alcohol. Its molecular formula is C₁₈H₂₈O₄. The compound is assigned CAS registry number 205687-01-0. Capsiate has been identified as having roles as a plant metabolite, a hypoglycemic agent, an anti-allergic agent, an antioxidant, an angiogenesis inhibitor, an anti-inflammatory agent, and a capsaicin receptor agonist; it is classified as a carboxylic ester, a monomethoxybenzene, and a member of the phenols.
The defining structural characteristic that separates capsiate from its closely related pungent analogue capsaicin lies at the central linkage between the aromatic vanillyl moiety and the branched-chain fatty acid: capsiate has an ester bond, whereas capsaicin has an amide bond at the equivalent position. Capsinoids are structurally similar to capsaicinoids, but they have an ester bond instead of an amide bond between the aromatic ring and the branched fatty acid; because of this difference, capsinoids have almost no pungency, unlike capsaicinoids. The key difference between capsaicinoids and capsinoids lies in this linkage: an amide bond in capsaicinoids and an ester bond in capsinoids.
Capsiate is the most abundant and most studied member of the capsinoid family. The major naturally occurring capsinoids are capsiate, dihydrocapsiate, and nordihydrocapsiate. The content ratio of capsiate to dihydrocapsiate to nordihydrocapsiate in the CH-19 Sweet cultivar is approximately 5:3:1, respectively. Capsiate, dihydrocapsiate, and nordihydrocapsiate are three capsinoids structurally similar to the pungent capsaicins, dihydrocapsaicin, and nordihydrocapsaicin. A newer, related class of non-pungent coniferyl esters — capsiconinoids (capsiconiate and dihydrocapsiconiate) — has also been isolated from the fruits of several Capsicum cultivars.
Capsiate and related capsinoids occur in fruits of the genus Capsicum (family Solanaceae). The capsinoid family is one of the natural constituents of the five domesticated chili peppers: Capsicum annuum, Capsicum frutescens, Capsicum chinense, Capsicum baccatum, and Capsicum pubescens. The canonical, highest-yielding natural source is a specific non-pungent cultivar. The Capsicum cultivar CH-19 Sweet is a non-pungent mutant derived from a pungent pepper strain, C. annuum CH-19; the fruits of CH-19 Sweet contain naturally occurring analogues of capsaicinoids — capsinoids. CH-19 Sweet produces large amounts of capsinoids, but most pungent Capsicum lines also produce capsinoids, in trace amounts.
Additional botanical sources have been identified or cultivated for capsinoid production. Targeted analysis of Capsicum chinense cv. Trinidad Pimento cell cultures indicated the presence of capsiate, dihydrocapsiate, and nordihydrocapsiate as key bioactive products in hydroethanolic extracts. In the 'Tabasco' accession (C. frutescens), capsiate and dihydrocapsiate were quantified, ranging from 3.09 to 58.76 and 1.80 to 6.94 μg/g DW, respectively. Capsinoids are present at a very low concentration (approximately 30 µg/g) in pepper fruit.
The low and variable natural yields from pepper plants have driven interest in alternative production strategies. Direct sourcing from Capsicum plants is hindered by the low and variable yields, which depend on genotype and environmental conditions, and by the pungent components of chili plants that act as irritants.
The biochemical origin of capsiate in Capsicum plants has been substantially elucidated. The Capsicum-specific capsaicin and capsiate biosynthetic pathways are branched from the lignin biosynthetic pathway in plants. Capsiate is synthesized from vanillyl alcohol rather than vanillylamine, in contrast to capsaicin, which is synthesized from vanillylamine. The vanillin reductase in the capsiate biosynthetic pathway is cinnamyl alcohol dehydrogenase (CAD), an enzyme also involved in lignin synthesis. The molecular reason CH-19 Sweet preferentially accumulates capsinoids rather than capsaicinoids is well established: enzyme assays revealed that pAMT (putative aminotransferase) activity catalyzing vanillylamine formation was completely lost in CH-19 Sweet placenta tissue, redirecting the pathway toward the ester-linked capsinoids.
Capsiate is commercially available as a purified or enriched extract standardized from non-pungent Capsicum annuum pepper. In research and clinical studies, it is administered primarily in oral forms. The capsules available in the market for its anti-obesity effect are also oily in nature, reflecting capsiate's poor water solubility. Capsiate faces challenges of low aqueous solubility and stability, and the lack of wider adoption of this nutraceutical probably accrues from these two factors. Advanced delivery systems under investigation include solid lipid nanoparticles, polymer nanoparticles, dendrimers, and non-aqueous nanoemulsions. In aqueous conditions, capsiate can undergo hydrolysis to yield its constituent acids and alcohols.
Capsiate as a chemically distinct and identified entity is a modern discovery, formally characterized for the first time in 1998. Capsinoids were first reported in pepper fruits from the low-pungent cultivar 'CH-19 Sweet' (C. annuum) by Kobata, Todo, Yazawa, Iwai, and Watanabe in 1998. This seminal publication in the Journal of Agricultural and Food Chemistry (Vol. 46, pp. 1695–1697) established the compound's formal chemical identity.
However, the parent plant genus Capsicum, from which capsiate is derived, carries an extremely long history of human use. A native of the Americas, where it has been cultivated for thousands of years, the Capsicum plant spread to other parts of the world following European colonization and trade. Peppers from Capsicum species are native to the tropical and humid zones of Central and South America; they are generally employed as condiments or nutrients, with a wide range of beneficial use in Indian, American, and Chinese therapeutic customs for the treatment of acne, inflammation of the joints, and indigestion.
While these traditional uses pertain to pungent capsaicinoid-containing peppers rather than to capsiate specifically, the non-pungent cultivar CH-19 Sweet was itself derived from a pungent Capsicum annuum parent. The word "chili" or "chilli" is a variation of "chil" derived from the Nahuatl (Aztec) dialect which referred to plants now known as Capsicum. As a purified, isolated compound distinct from whole-pepper preparations, capsiate has no documented traditional medicinal use independent of the broader history of pepper-based therapies. Its investigation as a specific pharmacologically active molecule is entirely a product of late 20th- and early 21st-century research.
Capsaicin is a pungent capsaicinoid and capsiate is a classic example of a non-pungent capsinoid; both bind to and activate their receptor, transient receptor potential vanilloid subfamily 1 (TRPV1), which is expressed in neuronal and non-neuronal tissues. Although capsaicin and capsiate activate TRPV1, fundamental differences exist in their lipophilicity and stability, which may affect their efficacy; capsaicin induces thermogenesis and nociception, while capsiate has been shown to cause thermogenesis but no nociception.
The transient receptor potential vanilloid 1 (TRPV1) receptor is the primary molecular target for capsiate's known pharmacological actions. Capsiate activates the cloned capsaicin receptor TRPV1, which functions as a molecular integrator of painful chemical and physical stimuli, including noxious heat (>48 °C) and low pH, with a potency similar to that of capsaicin. The key difference is that capsiate does not produce the oral burning sensation associated with capsaicin because of pharmacokinetic barriers to sensory neurons. Two mechanisms are proposed to explain the poor accessibility of capsiate to sensory neurons that exist behind physiological barriers; one possibility is that capsiate is trapped in the lipid phase of the epithelium or cornea due to its high lipophilicity. Capsiate does not exhibit irritancy-related effects on the oral cavity or eye.
Research has also explored whether capsiate activates TRP channels beyond TRPV1. Like capsaicin, capsiate is thought to enhance energy metabolism by activating the sympathetic nervous system and suppressing inflammation, but the underlying mechanisms are not entirely certain; capsiate can activate TRPV1, and investigators have explored whether capsinoids also activate other TRP channels.
The best-characterized downstream effect of TRPV1 activation by capsiate is stimulation of adaptive thermogenesis. Oral administration of capsiate has been shown to stimulate the TRPV1 receptor, which in turn raises lipolysis of fat tissues through the sympathetic nervous system and thermogenesis. Dietary capsaicin and capsinoids are known to decrease body fat and increase energy expenditure and brown adipose cell (BAC)-mediated thermogenesis through a neurogenic mechanism.
At the molecular level in adipose tissue, high-fat diet suppressed the mRNA levels of TRPV1, SiRT-1, PRDM-16, PGC-1α, BMP8b, UCP-1, and PPARα; capsiate slightly but significantly elevated UCP-1 mRNA in a mouse model study comparing capsiate to capsaicin. Functional TRPV1 expression is detected in mouse brown adipose tissue per se, and its expression level correlates with brown adipogenesis; by inducing TRPV1-mediated Ca²⁺ influx, capsaicin and related compounds can directly modulate either brown adipogenesis or brown adipocyte activation.
Capsiate is like capsaicin in terms of prevention of gastrointestinal and cardiovascular diseases, pain relief, and its role as a potent anticarcinogenic agent. Capsinoids have potential anti-cancer activity and antioxidant activity. There is a positive correlation between the levels of capsaicin and its analogues and the antioxidant activity of peppers of the genus Capsicum.
The anti-angiogenic activity of capsiate and dihydrocapsiate was found to be independent of the TRPV1 receptor; the antiangiogenic activities of capsiate and dihydrocapsiate were compared to those shown by capsaicin, and these non-pungent capsaicinoids may be more important than capsaicin in the treatment of cancer, with no records of other natural and synthetic capsaicin analogues having antiangiogenic action.
The most robustly studied application of capsiate in humans is its effect on resting energy expenditure (REE) and fat oxidation. Multiple clinical trials and meta-analyses have examined this question.
A landmark clinical trial by Snitker et al. (2009), published in The American Journal of Clinical Nutrition, enrolled 80 men and women (mean age 42 ± 8 years, mean BMI 30.4 ± 2.4) in a randomized controlled design. Forty women and 40 men were randomly assigned to a capsinoid or placebo group; capsinoids were well tolerated; mean weight change was 0.9 ± 3.1 kg in the capsinoid group and 0.5 ± 2.4 kg in the placebo group (P = 0.86); there was no significant group difference in total change in adiposity, but abdominal adiposity decreased more in the capsinoid group.
Snitker et al. reported a significant reduction in adiposity and an elevation of energy expenditure after a 12-week treatment with capsinoids in middle-aged and slightly obese human subjects.
A 2012 meta-analysis by Ludy and Mattes critically reviewed and pooled available human data. Evidence indicates that capsaicin and capsiate both augment energy expenditure and enhance fat oxidation, especially at high doses. SMD with 95% confidence intervals showed that capsiate increases energy expenditure overall as well as at intermediate and high doses; capsiate had no significant effect on energy expenditure at low doses. Capsiate also enhanced fat oxidation overall as well as at high doses; capsiate had no significant effect on substrate oxidation at low or intermediate doses.
A systematic review of randomized controlled trials examining capsaicinoids and capsinoids and weight management concluded: consumption of capsaicinoids increases energy expenditure by approximately 50 kcal/day, and this would produce clinically significant levels of weight loss in 1–2 years.
A 2018 meta-analysis (Zsiborás et al., Critical Reviews in Food Science and Nutrition) synthesized human studies and reported that agonizing TRPV1 results in an increase in sympathetic nervous system activity, leading to an increase in energy expenditure (58 kcal/day) and decreased respiratory quotient, indicating a rise in fat oxidation.
A more recent acute-response randomized trial by 13 healthy men examined capsiate supplementation with and without exercise. The study examined the effect of capsiate supplementation on energy intake, self-reported appetite-related sensations, energy expenditure, fat oxidation, and autonomic parameters; thirteen healthy men completed four randomized trials — two control conditions and two exercise conditions, each with and without capsiate supplementation.
A 10-week resistance training study using 12 mg of capsiate per day found that capsiate supplementation (12 mg, 7 days per week) did not change adipose tissue–derived hormones, appetite, body composition, or muscle strength in healthy untrained, non-obese men. This suggests that the thermogenic effects may be context- and population-dependent.
Evidence strength: The evidence for modest acute increases in energy expenditure and fat oxidation in humans at intermediate-to-high doses is consistent across multiple small-to-medium randomized controlled trials and is supported by several meta-analyses. The magnitude of effect (approximately 50–58 kcal/day) is real but modest. Evidence for clinically meaningful weight loss in humans is weaker; most trials are short-term (under 12 weeks), use small samples, and show mixed results on body composition endpoints.
A series of studies conducted primarily at Hokkaido University, Japan, investigated the specific role of brown adipose tissue in capsinoid-induced thermogenesis in humans. In a crossover study reported by Yoneshiro et al. (2012, American Journal of Clinical Nutrition), 18 men underwent positron emission tomography (PET) examination under standardized cold conditions to classify them as BAT-positive or BAT-negative. They were all treated with a single dose of capsinoids (9 mg) or placebo, subjected to calorimetry, and after 1–3 weeks the experiment was repeated in crossover mode; since the highest energy expenditure response occurred in BAT-positive subjects after administration of capsinoids, the authors concluded that capsinoids, acting at the intestinal level through TRPV1, can activate already-present BAT and may also recruit new BAT in subjects who lack it.
Only in humans with metabolically active BAT, but not in those without it, did a single oral dose of 9 mg capsinoids increase energy expenditure; however, the evidence to support the role of capsinoids in BAT activation and modulation of energy expenditure remains tenuous due to very limited proof via gold-standard PET imaging in capsinoid studies.
Chronic BAT recruitment was also studied. In a clinical investigation by Yoneshiro et al. (2013, Journal of Clinical Investigation), subjects with low BAT activity underwent daily capsinoid ingestion or cold stimulation for 6 weeks: treatment with capsinoids resulted in BAT accumulation and increased energy expenditure in individuals who previously had low or undetectable BAT. These findings indicated that capsinoid ingestion can mimic the chronic effects of cold exposure on BAT.
A study by Nirengi et al. confirmed: 6 weeks of capsinoid treatment induced an increase in BAT activity as measured by ¹⁸F-FDG PET/CT scan; daily capsinoid ingestion over 8 weeks showed that the total hemoglobin change (assessed by near-infrared time-resolved spectroscopy every 2 weeks at 27°C in the supraclavicular region) was significantly greater in the capsinoid group.
However, a more recent study using ¹⁸F-FDG PET imaging at the standard uptake value (SUV) threshold found: acute capsinoid ingestion increased energy expenditure in BAT-positive participants but apparently did not induce detectable BAT activity using a standard SUV cutoff — a finding that seemingly contradicts the hypothesis that capsinoid ingestion increases energy expenditure through the activation of BAT in humans. The researchers noted that ¹⁸F-FDG-PET imaging may be less sensitive for BAT activity detection than energy expenditure measurement, which partially reconciles the conflicting results.
Evidence strength: The BAT-activation hypothesis is biologically plausible and supported by convergent findings from indirect calorimetry, PET/CT, and near-infrared spectroscopy. Positive findings are consistent in BAT-positive individuals. However, the evidence base consists of small studies (n often <25), methodological heterogeneity, and at least one PET study that failed to confirm BAT activation by the gold-standard method. The overall evidence is promising but not yet conclusive.
The chronic administration of capsiate, derived from highly concentrated CH-19 sweet pepper fruit, was reported to enhance the loss of fat in both humans and animal models. Capsiate, a non-pungent capsaicin analogue, is known to suppress body fat accumulation and reduce body weight by enhancing energy expenditure in both mice and humans. In the Snitker et al. (2009) trial specifically, a significant reduction in adiposity and an elevation of energy expenditure were reported after a 12-week treatment with capsinoids in middle-aged and slightly obese human subjects.
In contrast, a 10-week trial in healthy untrained non-obese men found that capsiate supplementation did not potentiate the benefits of 10 weeks of resistance training. The balance of evidence suggests body-composition effects in humans are modest, may depend on baseline metabolic status (including BAT content), and are not reliably replicated across all populations.
Evidence strength: Preliminary-to-moderate. Small, short-duration clinical trials show modest reductions in abdominal adiposity; the effect on overall body weight in adequately powered trials is not statistically significant. No large-scale, long-duration RCT has been conducted.
Modifications of the capsaicin pharmacophore have yielded capsaicinoids such as capsiate and nordihydrocapsiate, which have only shown anticancer properties without any reported carcinogenic effects. These non-pungent capsaicinoids (capsiate and its associated compounds) may be more important than capsaicin in the treatment of cancer; however, there are no records of other natural and synthetic capsaicin analogues having antiangiogenic action. The anti-angiogenic mechanism has been characterized as independent of TRPV1, representing a potentially distinct pathway from the thermogenic effects.
Evidence strength: Preclinical (in vitro and animal models) only. Clinical studies are limited, which may be related to some of the inherent challenges associated with capsaicin and related compounds in the limited clinical trials. No human clinical trials have evaluated capsiate specifically for cancer prevention or treatment.
Peppers from Capsicum species are a good source of provitamin A, vitamins E and C, carotenoids, and phenolic compounds such as capsaicinoids and flavonoids; all of these compounds are associated with antioxidant as well as other biological activities. Capsiate, as a phenolic ester, participates in this antioxidant profile. Evidence at this level remains in vitro or indirect from studies of mixed pepper extracts; dedicated human clinical trials measuring antioxidant endpoints for capsiate alone are not available in the literature.
Evidence strength: Preliminary; in vitro and extrapolated from broader capsaicinoid/capsinoid research.
Capsiate has been explored in the treatment of obesity, metabolic disorders, cancer, cardiovascular disorders, and gastrointestinal disorders. Animal studies have examined effects on glucose metabolism. Both capsaicin and capsiate reduced body mass gain, visceral fat accumulation, serum leptin concentrations, and improved glucose tolerance without modulating energy intake in diabetic rats, with greater antidiabetic actions in capsiate compared with capsaicin. These findings have not yet been translated into definitive human clinical trials for metabolic or glycemic endpoints specific to capsiate.
Evidence strength: Largely preclinical (animal models). Human evidence for metabolic or glycemic outcomes is indirect or absent.
The following dosages have been reported in published research; they are presented strictly as reported in the cited studies and do not represent recommendations:
Formulation is a noted challenge: designing an effective dosage form with complete absence of water is a challenge in itself; the capsules available in the market for the anti-obesity effect are oily in nature.
A key practical advantage of capsiate over capsaicin is its absence of oral pungency and irritation. Capsaicin induces thermogenesis and nociception, while the different kinetics of capsiate result in thermogenesis without nociception in the oral cavity. Capsiate does not exhibit irritancy-related effects on the oral cavity or eye. In the Snitker et al. (2009) controlled trial, capsinoids were well tolerated.
Preclinical toxicology data have been reported. Preclinical toxicology and safety studies suggest that capsinoids have a low potential for harm, with NOAELs (no observed adverse effect levels) of 1000 mg/kg/day reported for both sexes in animal studies. Capsiate exhibits itself as a lesser toxic substitute for capsaicin.
Capsiate's ester bond confers important physicochemical and pharmacokinetic properties that differ from capsaicin's more hydrolytically stable amide bond. In aqueous conditions, capsiate can undergo hydrolysis to yield its constituent acids and alcohols, which represents a primary metabolic pathway in the gastrointestinal tract. The metabolite vanillyl alcohol is a known, naturally occurring compound. This hydrolytic instability is also the reason why capsiate does not reach sensory neurons in the mouth and skin at levels sufficient to activate TRPV1-mediated pain — it is rapidly degraded in the aqueous mucosal environment before penetrating to nociceptive nerve endings.
Capsiate activates TRPV1 and stimulates the sympathetic nervous system. Oral administration of capsiate raises lipolysis of fat tissues through the sympathetic nervous system. Based on this mechanism, theoretical interactions with sympathomimetic agents, antihypertensive medications, or drugs with a narrow cardiovascular therapeutic window are pharmacologically plausible, though specific drug–capsiate interaction studies in humans are not available in the peer-reviewed literature surveyed.
The evidence to support the role of capsinoids in BAT activation and modulation of energy expenditure remains tenuous due to very limited proof via the gold-standard positron emission tomography imaging in capsinoid studies. Most human clinical trials to date have been short in duration (under 12 weeks), small in sample size, and have used mixed capsinoid preparations rather than pure capsiate. The clinical significance of the observed thermogenic and body composition effects for long-term health outcomes has not been definitively established.
Health conditions that Capsiate may help support.
Capsiate is a non-pungent analog of capsaicin found in sweet peppers, studied as a thermogenic agent that increases energy expenditure via TRPV1-like mechanisms without the oral irritation of capsaicin. A 2012 meta-analysis (Ludy et al.) confirmed effects on energy balance in humans. It is noted in the 2016 Phytotherapy Research systematic review as a more tolerable thermogenic alternative to capsaicin.
Body systems that Capsiate may help support.
Go back